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Abstract
Background: Alzheimer’s disease has become a growing socio-economical concern in developing countries where
increased life expectancy is leading to large aged populations. While curing Alzheimer’s disease or stopping its
progression does not appear within reach in a foreseeable future, new therapies capable of delaying the
pathogenesis would represent major breakthroughs.
Presentation of the hypothesis: The growing number of medical benefits of cannabinoids, such as their ability to
regulate age-related processes like neuroinflammation, neurogenesis and memory, raise the question of their
potential role as a preventive treatment of AD.
Testing the hypothesis: To test this hypothesis, epidemiological studies on long term, chronic cannabinoid users
could enlighten us on the potential benefits of these compounds in normal and pathological ageing processes.
Systematic pharmacological (and thus more mechanistic) investigations using animal models of Alzheimer’s disease
that have been developed would also allow a thorough investigation of the benefits of cannabinoid
pharmacotherapy in the pathogenesis of Alzheimer’s disease.
Implications of the hypothesis: The chronic administration of non-selective cannabinoids may delay the onset of
cognitive deficits in AD patients; this will dramatically reduce the socio-economic burden of AD and improve the
quality of life of the patients and their families.
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Background
Alzheimer’s disease (AD) is the most common neurode-
generative disease and accounts for the majority of diag-
nosed dementia after age 60. Currently available drugs
only produce temporary relief from some cognitive
symptoms without delaying, stopping or reversing the
neuropathology. Due to poor efficacy of current treat-
ments and the likely delay to implement future safe and
efficacious treatments, there is an opportunity to develop
preventive approaches based on currently available
knowledge regarding the pathogenesis of AD. Neuroin-
flammation has attracted growing attention due to its
slow progression and chronic nature, particularly during
normal aging, as well as its involvement in various neuro-
degenerative diseases [1]. Neuroinflammation has thus
been targeted by numerous pharmacological agents [1-4].
Elderly patients (65 years and older) treated with non-
steroidal anti-inflammatory drugs (NSAIDS) for 24
months exhibited a surprisingly lower prevalence of
developing AD years later (follow up of 8 years, [5]). Sub-
sequent clinical trials with NSAIDS were conducted on
AD patients but failed to demonstrate significant benefi-
cial effects [6]. Indeed, studies show that NSAIDS tend to
lose efficacy in aged animals [7], which may account for
the negative results of the clinical trials [6].
Most recent therapies have been designed and tested
first in transgenic mice models and rarely take into
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95% of AD cases are non-familial and occur in the latter
stages of life, basic knowledge on normal ageing pro-
cesses and the way to delay them appear as a logical
approach to tackle AD [8].
The endocannabinoid system has recently raised a great
deal of interest in AD research, notably as a powerful
modulator of neuronal activity (i.e. glutamatergic neurons)
or inflammatory processes [9-11]. Cannabinoids already
have numerous common uses as anti-emetics during can-
cer treatment or relief from inflammation-related pain
[12]. Natural or synthetic cannabinoids exhibit variable
specificity and selectivity for cannabinoid receptors [2];
this fact is particularly important in the light of the well-
known psychoactive effect of some of these compounds
due to their actions on neuronal CB1 receptors [13].
Despite the challenge of targeting receptors that poten-
tially disrupt learning and memory, neuroprotective
approaches have been taken to circumvent those effects by
targeting more specifically the CB2 receptor, by modulat-
ing the degradation pathway of endocannabinoids, or by
using low, non-psychoactive doses of non-selective ago-
nists of CB1/CB2 receptors [14-16]. Indeed, in exploring
the potential of cannabinoids in a preventive approach, we
have recently demonstrated that non-psychoactive doses
of a non-specific cannabinoid agonist (WIN-55,212-2) can
decrease chronic neuroinflammation, restore hippocampal
neurogenesis and improve memory in aged rats [17-20].
Hence cannabinoids are endowed with unique procliv-
ities that warrant their use in the prevention of age-
associated cognitive decline.
Presentation of the hypothesis
From the above, we postulate that modulation of the
endocannabinoid system in recently diagnosed AD
patients by daily administration of low-doses of cannabi-
noids could at minimum delay the disease progression.
In the long run, a preventive approach aimed at the gen-
eral ageing population may become appropriate.
Testing the hypothesis
Epidemiological studies have already been conducted on
cannabis users, in particular in adolescents for the still
controversial role of cannabinoids in the development of
psychosis such as schizophrenia [21]. The popularity of
cannabis among a significant number of people, notably in
the 1970’s, and the fact that some of these people still use
cannabis chronically, could allow the identification of a
cohort of chronic users who are currently over 60 years of
age. If such a cohort could be constituted and cognitively
tested, it would contribute to an evaluation of the effects
of long term use of cannabinoids on brain ageing.
Further studies should be carried out on animals to
address preclinical questions. These should involve
chronic administration of different non-selective canna-
binoids (e.g. WIN-55,212-2, cannabinol, Δ
9-THC, HU-
210, anandamide, or inhibitors of endocannabinoid
degradation) in mouse models of AD. Indeed, mice have
been genetically engineered to incorporate human muta-
tions of genes encoding the amyloid precursor protein
(APP) and presinilins (PS) linked to familial cases of
AD, and/or the hyperphosphorylation of Tau protein
[22-26]. Despite their “artificial” nature, transgenic mice
represent a very convenient model to test various
hypotheses in young and aged animals with reasonable
efficiency in terms of time and costs. Among mouse
models, hallmarks of AD pathology can be reproduced
(amyloid plaques and/or neurofibrillary tangles, often
associated with neuroinflammation) with an onset and
progression depending on the “aggressivity” or number
of mutations carried by the animals. These models
would provide an interesting array of experimental con-
ditions to test our hypothesis and notably the effects of
cannabinoids on:
- Neuroinflammatory markers, now commonly asso-
ciated with the development of the disease, such as
glial cell responses and their inflammation-related
production of specific inflammatory markers. Modu-
lators of both inflammatory responses and APP/Ab
metabolism such as the metalloproteinases (ADAM-
10, ADAM-17, MMP-2, -9, -14 and -25) remain to
be explored.
- The expression of APP and its catabolites Ab and
sAPPa, as representatives of the amyloidogenic and
non-amyloidogenic pathways, respectively. It will be
of particular interest to evaluate the ratio of intracel-
lular vs extracellular Ab, and Ab oligomers vs fibrils,
considering the specificities of their toxicity.
- Tau protein hyperphosphorylation leading to for-
mation of neurofibrillary tangles.
- Neurogenic processes that could slow or compen-
sate ongoing neurodegeneration.
- Cognitive abilities tested using a variety of beha-
vioral tasks.
Implications of the hypothesis
The complex nature of AD advocates for the use of a mul-
timodal drug approach that could protect from the various
processes underlying neurodegeneration and thus, at mini-
mum, delay the pathological process. The expected benefit
from a chronic treatment aimed at stimulating the endo-
cannabinoid system is a delayed progression of AD: i.e.
reduced inflammation, sustained potential for neurogen-
esis, reduced accumulation of Ab, reduced hyperpho-
sphorylation of Tau and delayed memory impairment.
Such results could lead to new therapeutic strategies that
target both the chronic inflammation and the decline in
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Most importantly, delaying disease progression will signifi-
cantly reduce the number of severely impaired AD
patients and thus reduce the growing socioeconomic bur-
den associated with this disease.
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